The impact of pharmacogenomics on gastrointestinal cancer therapy

Pharmacogenomics

Volumn 3, Issue 5, 2002, Pages 625-633

  Seufferlein, Thomas ^a   Boehm, Bernhard O ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

5 FU; Gastrointestinal cancer; Genetic polymorphism; Irinotecan; Oxaliplatin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CARBOXYLESTERASE; CISPLATIN; CYTOCHROME P450 3A4; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; DNA TOPOISOMERASE; DRUG METABOLIZING ENZYME; FLOXURIDINE PHOSPHATE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DNA SYNTHESIS; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; LUNG CANCER; NEUROTOXICITY; PHARMACOGENOMICS; RECTUM CANCER; REVIEW; SENSORY NEUROPATHY; TANDEM REPEAT;

ANIMALS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; PHARMACOGENETICS;

EID: 0036739543     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.5.625     Document Type: Review

References (64)

1. Brookes AJ: The essence of SNPs. Gene 234, 177-186 (1999).
2. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB: Clinical pharmakokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res. 47, 2203-2206 (1987).
3. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin. Oncol. 12, 2248-2253 (1994).
4. Lu Z, Zhang R, Diasio RB: Diydropyrimidine dehydrogenase activity in human peripheral blood mononuclar cells and liver: population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53, 5433-5438 (1993).
5. Diasio RB, Beavers T, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyridinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81, 47-51 (1988).
6. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 5, 2006-2011 (1999).
7. van Kuilenburg AB, Muller EW, Haasjes J et al.: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+ 1G to A mutation causing DPD deficiency. Clin. Cancer Res. 7, 1149-1153 (2001).
8. Raida M, Schwabe W, Häusler P et al.: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 7, 2832-2839 (2001).
9. Relling M, Dervieux T: Pharmacogenetics and cancer therapy. Nat. Rev. Cancer 1, 99-108 (2001).
10. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98, 610-615 (1996).
11. McLeod HL: Nomenclature for human DPYD alleles. Pharamcogenetics 8, 455-459 (1998).
12. Etienne MC, Cheradame S, Fischel JL et al.: Response to fluorouracil therapy in cancer patients: the role of tumoural dihydropyrimidine dehydrogenase activity. J. Clin. Oncol. 13, 1663-1670 (1995).
13. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidilate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anti-Cancer Res. 19, 3249-3252 (1999).
14. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′ terminal regulatory region of the human gene for thymidilate synthase. Cell Struct. Funct. 20, 191-197 (1995).
15. Etienne MC, Chazal M, Laurent-Puig P et al.: Prognostic value of tumoural thymidilate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin. Oncol. 20, 2832-2843 (2002).
16. Kawakami K, Salonga D, Park JM et al.: Different lenghts of a polymorphic repeat sequence in the thymidilate synthase gene affect translational effciency but not its gene expression. Clin. Cancer Res. 7, 4096-4101 (2001).
17. Yamachika T, Nakanishi H, Inada K et al.: A new prognostic factor for colorectal carcinoma, thymidilate synthase and its therapeutic significance. Cancer 82, 70-77 (1998).
18. Kralovanszky J, Koves I, Orosz Z et al.: Prognostic significance of the thymidilate biosynthetic enzymes in human colorectal tumours. Oncology 62, 167-174 (2002).
19. Edler D, Glimelius B, Hallström M et al.: Thymidilate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluouracil-based chemotherapy. J Clin. Oncol. 20, 1721-1728 (2002).
20. Tomiak A, Vincent M, Earle CC et al.: Thymidilate synthase expression in stage II and III colon cancer: a retrospective review. Am. J. Clin. Oncol. 24, 597-602 (2001).
21. Allegra CJ, Parr AL, Wold LE et al.: Investigation of the prognostic and predictive value of thymidilate synthase, p53 and Ki-67 in patients with locally advanced colon cancer. J. Clin. Oncol. 20, 1735-1743 (2002).
22. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H: Thymidilate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin. Cancer Res. 6, 1378-1384 (2000).
23. Johnston PG, Lenz HJ, Leichman CG et al.: Thymidilate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res. 55, 1407-1412 (1995).
24. Leichman CG, Lenz HJ, Leichman L et al.: Quantitation of intratumoural thymidilate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15, 3223-3229 (1997).
25. Shirota Y, Stoehlmacher J, Brabender J et al.: ERCC1 and thymidilate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19, 4298-4304 (2001).
26. Takamura M, Nio Y, Yamsawa K, Dong M, Yamaguchi K, Itakura M: Implication of thymidilate,synthase in the outcome of patients wich invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anti Cancer Drugs 13, 75-85 (2002).
27. Villafranca E, Okruzhnov Y, Dominguez MA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidilate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin. Oncol. 19, 1779-1786 (2001).
28. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidilate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85, 827-830 (2001).
29. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidilate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics 1, 65-70 (2001).
30. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidilate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19, 383-386 (2001).
31. Saltz LB, Cox JV, Blanke C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J Med. 343,90 5-914 (2000).
32. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K: Antitumour activity of a camptothecin derivative, CPT- 11, against human tumour xenografts in nude mice. Cancer Chemother. Pharmacol. 28, 192-198 (1991).
33. Akabayashi A: Questions raised over release of side effects data in Japan. Lancet 350, 124 (1997).
34. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N. Engl. J. Med. 345, 144-145 (2001).
35. Iyer L, King, CD, Whtington PF et al.: Genetic predisposition to the metablism of irinotecan (CPT- 11). Role of uridine diposphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin. Invest. 101, 847-854 (1998).
36. Iyer L, Hall D, Das S et al.: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65, 576-582 (1999).
37. Takasuna K, Hagiwara T, Hirohashi M et al.: Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumour camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56, 3572-3577 (1996).
38. Ritter JK, Chen F, Sheen YY et al.: A novel complex locus UGT1 endcodes human bilirubin, phenol and other UDP-glucuronosyltransferase isoenzymes with identical carboxyl termini. J. Biol. Chem. 267, 3257-3261 (1992).
39. Senafi SB, Clarke DJ, Burchell B: Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J. 303, 233-240 (1994).
40. MacKenzie PI, Owens IS, Burchell B et al.: The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7, 255-269 (1997).
41. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B: Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581 (1996).
42. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95, 8170-8174 (1998).
43. Bosma PJ, Chowdury JR, Bakker C et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl J. Med. 333, 1171-1175 (1995).
44. Aono S, Adachi Y, Uyama E et al.: Analysis of genes for bilirubin UDP-glucuronosltransferase in Gilbert's syndrome. Lancet 345, 958-959 (1995).
45. Beutler E, Gelbart T, Demiona A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95, 8170-8174 (1998).
46. Akaba K, Kimura T, Sasaki A et al.: Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46, 21-26 (1998).
47. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ: Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54, 3723-3725 (1994).
48. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
49. Iyer L, Janisch L, Das S et al.: UGT1A1 promoter genotype corelates with pharmacokinetics of irinotecan (CPT-11). Proc. Am. Soc. Clin. Oncol., 19, 178A (2000)
50. Wassermann E, Myara A, Lokiec F et al.: Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol. 8, 1049-1051 (1997).
51. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A: Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneral administration of CPT-11. Jpn J. Cancer Res. 84, 697-702 (1993).
52. Santos A, Zanetta S, Cresteil T et al.: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A in humans. Clin. Cancer Res. 6, 2012-2020 (2000).
53. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W: Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32, 165-206 (2002).
54. Rivory P, Riou JF, Haaz MC et al.: Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 56, 3689-3694 (1996).
55. Dodds H, Haaz MC, Riou J, Robert J, Rivory LP: Identification of a new metabolite of CPT-11 (irinotcan): pharmacological properties and activation to SN-38. J. Pharmacol. Exp. Ther. 286, 578-583 (1998).
56. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz S: Modification of clinical presentation of prostate tumours by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998).
57. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60, 1189-1192 (2000).
58. Khanna R, Morton CL, Danks MK, Potter PM: Proficient metabolism of irinotcan by a human intestinal carboxylesterase. Cancer Res. 60, 4725-4728 (2000).
59. Schmoll HJ, Cassidy J: Integrating oxaliplatin into the managment of colorectal cancer. Oncologist 6, 24-28 (2001).
60. Khushalani NI, Leichman CG, Proulx G et al.: Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J. Clin. Oncol. 20, 2844-2850 (2002).
61. Stoehlmacher J, Ghaderi V, Iobal S et al.: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anti-Cancer Res. 21, 3075-3079 (2001).
62. Stoehlmacher J, Park DJ, Zhang W et al.: Association between glutathione S-transferase P1, T1 and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 94, 936-942 (2002).
63. Innocenti F. Ratain MJ: Correspondence re: Raida, M. et al. prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 8, 1314-1316 (2002).
64. van Cutsem E, Douillard JY, Kohne CH: Toxicity of irinotecan in patients with colorectal cancer. N. Engl. J. Med. 345, 1351-1352 (2001).